Key Analyst's EPS Estimates: Johnson & Johnson's (JNJ)

Johnson & Johnson’s Consumer Segment’s 1Q17 Earnings

Girard Securities Inc. Sells 591 Shares of Johnson & Johnson (JNJ)

Bremer Trust National Association boosted its position in shares of Johnson & Johnson by 1.9% in the third quarter. Bremer Trust National Association now owns 22,727 shares of the company's stock valued at $2,685,000 after buying an additional 432 shares during the last quarter. Independence Advisors LLC boosted its position in shares of Johnson & Johnson by 52.5% in the third quarter. Roundview Capital LLC now owns 45,335 shares of the company's stock valued at $5,223,000 after buying an additional 855 shares in the last quarter. Sandhill Capital Partners LLC boosted its position in shares of Johnson & Johnson by 2.7% in the fourth quarter. Wechter Feldman Wealth Management Inc. purchased a new stake in Johnson & Johnson during the fourth quarter worth $209,000. Managed Asset Portfolios LLC now owns 135,201 shares of the company's stock valued at $15,577,000 after buying an additional 11,312 shares in the last quarter. Institutional investors own 65.30% of the company's stock.

Shares of Johnson & Johnson (NYSE:JNJ) opened at 121.37 on Thursday. Fred Alger Management Inc. now owns 76,506 shares of the company's stock valued at $8,814,000 after buying an additional 11,262 shares in the last quarter. The 50 day moving average of NYSE:JNJ is 125.32 and the 200 day moving average is 118.02. Johnson & Johnson has a one year low of $109.32 and a one year high of $129.00. Johnson & Johnson also was the recipient of unusually large options trading activity on Tuesday. Stock investors bought 3,039 put options on the company. This represents an increase of approximately 415% compared to the typical volume of 590 put options.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 18th. The company reported $1.83 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.06.

Johnson & Johnson's revenue has risen over the past few years following its restructuring of its business segments and the strong performances of a few of its key products, including Xarelto, Zytiga, Remicade, Stelara, and Olysio. During the same period in the previous year, the company posted $1.68 EPS. Equities research analysts predict that Johnson & Johnson will post $7.05 earnings per share for the current year. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and worldwide copyright law. The original version of this news story can be read at https://transcriptdaily.com/2017/04/20/girard-securities-inc-sells-591-shares-of-johnson-johnson-jnj.html.

Several brokerages have recently commented on JNJ. Barclays PLC restated an "equal weight" rating and set a $130.00 target price (up previously from $125.00) on shares of Johnson & Johnson in a research report on Monday. BTIG Research reaffirmed a "hold" rating on shares of Johnson & Johnson in a research report on Wednesday.

Over the last 52 weeks Johnson & Johnson's stock price has increased by 12.65% from 107.95 to 121.61. Equity research analysts have given opinions on where they foresees the stock level.

In other news, VP Paulus Stoffels sold 22,000 shares of Johnson & Johnson stock in a transaction on Wednesday, February 15th.

Analyst recommendation for this stock stands at 2.50. Following the completion of the sale, the vice president now directly owns 127,650 shares in the company, valued at approximately $14,972,068.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The short ratio in the company's stock is documented at 2.60 and the short float is around of 0.68%.

Otras noticias